Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Remifentanil in Gastrectomy Recovery
NCT04529135Completed
- Sponsor
- Gangnam Severance Hospital
- Start
- Aug 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine in gastric cancer (GC) (2 arms), sponsored by Gangnam Severance Hospital. Primary endpoint: Postoperative recovery time at 3 months. Started Aug 2020; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04529135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04529135.